International technology transfer of a GCLP-compliant HIV-1 neutralizing antibody assay for human clinical trials

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Ozaki, Daniel A ^a   Gao, Hongmei ^a   Todd, Christopher A ^a   Greene, Kelli M ^a   Montefiori, David C ^a   Sarzotti Kelsoe, Marcella ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; DIETHYLAMINOETHYLDEXTRAN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ACCURACY; ARTICLE; CELL CULTURE; CLINICAL TRIAL (TOPIC); GOOD LABORATORY PRACTICE; HIV 1 NEUTRALIZING ANTIBODY ASSAY; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOASSAY; SENSITIVITY AND SPECIFICITY; STAFF TRAINING; TECHNOLOGY; VALIDATION PROCESS; VIRUS NEUTRALIZATION; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HELA CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; INTERNATIONAL COOPERATION; METHODOLOGY; PRACTICE GUIDELINE; REPRODUCIBILITY; SERODIAGNOSIS; STANDARD; TITRIMETRY;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

AIDS VACCINES; ANTIBODIES, NEUTRALIZING; CLINICAL TRIALS AS TOPIC; DEAE-DEXTRAN; GUIDELINE ADHERENCE; HEALTH PLAN IMPLEMENTATION; HELA CELLS; HIV ANTIBODIES; HIV-1; HUMANS; INTERNATIONALITY; NEUTRALIZATION TESTS; QUALITY ASSURANCE, HEALTH CARE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TECHNOLOGY TRANSFER; TITRIMETRY;

EID: 84856398863     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030963     Document Type: Article

References (18)

1. Montefiori D, Sattentau Q, Flores J, Esparza J, Mascola J, (2007) Antibody-based HIV-1 vaccines: recent developments and future directions. PLoS Med 4: e348.
2. Ezzelle J, Rodriguez-Chavez IR, Darden JM, Stirewalt M, Kunwar N, et al. (2008) Guidelines on good clinical laboratory practice: bridging operations between research and clinical research laboratories. J Pharm Biomed Anal 46: 18-29.
3. Stiles T, Grant V, Mawybey N, (2003) Good Clinical Laboratory Practice: A Quality System for Laboratories which undertake the Analyses of Samples from Clinical Trials Ipswich, United Kingdom British Association of Research Quality Assurance (BARQA).
4. (2005) The Global HIV/AIDS Vaccine Enterprise: scientific strategic plan. PLoS Med 2: e25.
5. (2010) The 2010 scientific strategic plan of the Global HIV Vaccine Enterprise. Nat Med 16: 981-989.
6. Montefiori DC, (2005) Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr Protoc Immunol Chapter 12: Unit 12 11.
7. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D, (1998) Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 72: 2855-2864.
8. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, et al. (2002) Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46: 1896-1905.
9. Fenyo EM, Heath A, Dispinseri S, Holmes H, Lusso P, et al. (2009) International network for comparison of HIV neutralization assays: the NeutNet report. PLoS One 4: e4505.
10. Stevens W, (2003) Good clinical laboratory practice (GCLP): the need for a hybrid of good laboratory practice and good clinical practice guidelines/standards for medical testing laboratories conducting clinical trials in developing countries. Qual Assur 10: 83-89.
11. Sarzotti-Kelsoe M, Cox J, Cleland N, Denny T, Hural J, et al. (2009) Evaluation and recommendations on good clinical laboratory practice guidelines for phase I-III clinical trials. PLoS Med 6: e1000067.
12. Gilmour JW, Stevens WS, Gray C, de Souza M, (2007) Laboratory expansion to large-scale international HIV preventive vaccine trials. Curr Opin HIV AIDS 2: 201-206.
13. Huang Y, Sato A, Wood B, Gill D, Kochar N, et al. (2009) Statistical design and analysis of the CAVD-VIMC Elispot transfer study 001. AIDS Vaccine 2009 Paris, France Retrovirology.
14. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, et al. (2005) Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 79: 10108-10125.
15. Todd CA, Greene KM, Yu X, Ozaki DA, Gao H, et al. (2011) Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells. J Immunol Methods.
16. Harmonisation ICo, editor (2005) ICH Tripartite Guideline: Validation of analytical procedures: text and methodology Q2(R1). pp. 1-13.
17. Piehler B, Nelson EK, Eckels J, Ramsay S, Lum K, et al. (2011) LabKey Server NAb: a tool for analyzing, visualizing and sharing results from neutralizing antibody assays. BMC Immunol 12: 33.
18. Gotch F, Gilmour J, (2007) Science, medicine and research in the developing world: a perspective. Nat Immunol 8: 1273-1276.